NCT05555836

Brief Summary

The prevalence of cognitive impairment in maintenance hemodialysis (MHD) patients is 3 to 5 times higher than that in ordinary people, so it is essential to find the associated risk factors in this population. This project intends to evaluate whether changes in cerebral blood flow during dialysis have an impact on cognitive function in middle-aged and elderly MHD patients and clarify their influence on brain imaging characteristics. MHD patients who started hemodialysis at 3 to 6 months were selected to examine the difference in middle cerebral artery flow rate before and after dialysis by transcranial Doppler ultrasound to reflect the changes in cerebral blood flow. Changes in the cognitive function scale assessment (memory, executive function, and other five cognitive domains) and brain magnetic resonance imaging examinations are planned to collect both at baseline and after a one-year follow-up. Then the investigator used the multiple linear regression method to analyze the effects of the difference in middle cerebral artery flow on the changes in cognitive function and the characteristics in brain imaging. The investigators anticipate that the characteristics of the influence of changes in cerebral blood flow on cognitive impairment in Chinese MHD patients will be elucidated in this study, which may provide crucial clinical evidence for finding preventive and intervention measures for cognitive impairment in this group of population.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
121

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2022

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

September 17, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

September 27, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

September 27, 2022

Status Verified

September 1, 2022

Enrollment Period

2.7 years

First QC Date

September 17, 2022

Last Update Submit

September 22, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Changes in cognitive function which is measured by MoCA scores changes after 1 year follow-up

    This study is going to apply neuropsychological battery tests in MoCA assessment and evaluate the changes of MoCA scores of MHD patients after one year of follow-up.

    This measurement is going to be completed within 1 year after the last participant enrolls

Eligibility Criteria

Age50 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Chinese Maintenace Hemodialysis Patients

You may qualify if:

  • Age greater than 50, no gender limitation;
  • End-stage renal disease, stable dialysis for 3-6 months;
  • Subjects voluntarily participated in the study and signed informed consent, and were able to participate in clinical data collection, neuropsychological assessment, transcranial Doppler ultrasound (TCD), head MRI, and 1-year follow-up.

You may not qualify if:

  • Congenital mental retardation or disturbance of consciousness, schizophrenia, or history of severe anxiety and depression (Hamilton Depression Scale score more than 17;
  • Long-term alcohol or psychotropic drug dependence;
  • Those who cannot complete the neuropsychological assessment due to visual impairment, hearing impairment, or limb dysfunction; less than 10 hours of dialysis per week;
  • Patients with poor detection of the bilateral temporal window by TCD examination and unable to cooperate with ultrasound examination;
  • Those who cannot undergo head MRI examination for various reasons.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beijing Shijitan Hospital affiliated to Capital Medical University

Beijing, 100038, China

Location

Study Officials

  • Yang Luo, MD, PhD

    Beijing Shijitan Hospital Affiliated to Capital Medical University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of nephrology Affiliation

Study Record Dates

First Submitted

September 17, 2022

First Posted

September 27, 2022

Study Start

January 1, 2022

Primary Completion

September 30, 2024

Study Completion

December 31, 2024

Last Updated

September 27, 2022

Record last verified: 2022-09

Locations